Leaflet: information for the user
Eplerenona Sandoz 25 mg film-coated tablets
Eplerenona Sandoz 50 mg film-coated tablets
Readthe entire leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What isEplerenona Sandozand what it is used for
2. What you need to know before you start takingEplerenona Sandoz
3. How to takeEplerenona Sandoz
4. Possible side effects
5. Storage ofEplerenona Sandoz
6. Contents of the pack and additional information
Eplerenona Sandozbelongs to a group of medicines known as selective aldosterone blockers. These blocking agents inhibit the action of aldosterone, a substance produced by the body that controls blood pressure and cardiac function. Elevated levels of aldosterone can produce changes in the body that lead to heart failure.
Eplerenona is used to treat heart failure to prevent worsening and reduce hospitalization if you have:
Do not take Eplerenona:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Eplerenona Sandoz
Children and adolescents
The safety and efficacy of eplerenona in children and adolescents have not been established.
Other medications and Eplerenona Sandoz
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Taking Eplerenona Sandoz with food and drinks
Eplerenona Sandoz can be taken with or without food.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication. Eplerenona has not been evaluated in humans during pregnancy.
The safety of eplerenona during breastfeeding is unknown. Your doctor will decide with you whether to stop treatment or breastfeeding.
Driving and operating machinery
After taking Eplerenona Sandoz, you may feel dizzy. If this happens, do not drive or operate machinery.
Eplerenona Sandoz contains lactose monohydrate and sodium
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per coated tablet; it is essentially “sodium-free”
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The Eplerenona Sandoz tablets can be taken with or without food. Swallow the tablets whole with plenty of water.
Eplerenona Sandoz is usually administered together with other medications for heart failure, for example, beta-blockers. The usual initial dose is one 25 mg tablet once a day, increasing after 4 weeks to 50 mg daily (one 50 mg tablet or two 25 mg tablets). The maximum dosage regimen is 50 mg per day.
Blood potassium determinations should be performed before starting treatment with Eplerenona Sandoz, during the first week, and one month after starting treatment or after a change in dose. Your doctor may adjust the dose based on your blood potassium levels.
If you have mild renal insufficiency, you should start treatment with one 25 mg tablet per day. If you have moderate renal insufficiency, you should start treatment with one 25 mg tablet every other day. These doses may be adjusted, if your doctor indicates, and in accordance with your blood potassium levels.
Eplerenona Sandoz is not recommended for patients with severe renal disease.
No initial dose adjustment is necessary for patients with mild to moderate liver insufficiency. If you have any liver or kidney disease, you may need to have your blood potassium levels checked more frequently (see also “Do not take Eplerenona Sandoz”).
In elderly patients: no initial dose adjustment is required.
In children and adolescents: Eplerenona Sandoz is not recommended.
If you take more Eplerenona Sandoz than you should
If you take more Eplerenona Sandoz than you should, inform your doctor or pharmacist immediately. If you have taken too much medication, the most likely symptoms will be low blood pressure (manifested as a feeling of fainting, dizziness, blurred vision, weakness, acute loss of consciousness) or hyperkalemia, high levels of potassium in the blood (manifested by muscle cramps, diarrhea, nausea, dizziness, or headache).
If you have taken more Eplerenona Sandoz than you should, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount used.
If you forget to take Eplerenona Sandoz
If it is almost time to take the next tablet, skip the dose you forgot and take the next tablet at the usual time.
Otherwise, take the tablet as soon as you remember, as long as more than 12 hours have elapsed since the usual time for taking the next tablet. Resume your usual medication schedule.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Eplerenona Sandoz
It is essential to continue taking Eplerenona Sandoz as instructed, unless your doctor tells you to stop treatment.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications,this medicationcan cause side effects, although not everyone will experience them.
If any of the following occur,seek medical attention immediately
These are symptoms of angioneurotic edema,a rare side effect (affecting up to 1 in 100 people).
Other reported side effects include:
Frequent side effects(may affect up to 1 in 10 patients):
Rare side effects(may affect up to 1 in 100 patients):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the packaging and the blister pack after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGREpointof the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Eplerenona Sandoz
The active ingredient is eplerenone.
Each Eplerenona Sandoz 25 mg tablet contains 25 mg of eplerenone.
Each Eplerenona Sandoz 50 mg tablet contains 50 mg of eplerenone.
The other excipients are:
Tablet core:
Lactose monohydrate
Microcrystalline cellulose (type 101)
Sodium croscarmellose
Hydroxypropyl methylcellulose (Type 2910)
Microcrystalline cellulose (type 102)
Sodium lauryl sulfate
Talc
Magnesium stearate
Tablet coating::
Lactose monohydrate
Hydroxypropyl methylcellulose (Type 2910)
Titanium dioxide (E171)
Macrogol 4000
Appearance of the product and contents of the package
Eplerenona Sandoz 25 mg tablets: are white or almost white, round, biconvex, approximately 6 mm in diameter, marked “CG3” on one face of the tablet and not marked on the other face.
Eplerenona Sandoz 50 mg tablets: are white or almost white, round, biconvex, approximately 8 mm in diameter, marked “CG4” on one face of the tablet and not marked on the other face.
The tablets are packaged in a PVC/aluminum blister inside a cardboard box containing 10, 20, 30, 50, 90, or 100 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid Spain
Manufacturer responsible
Laboratorios LICONSA S.A.
Avenida Miralcampo 7, Polígono Industrial Miralcampo
19200 Azuqueca de Henares, Guadalajara
Spain
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Genericon Pharma Gesellschaft m.b.H.,
Hafnerstrasse 211
8054 Graz,
Austria
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Austria:Eplerenon +pharma 25/50 mg Filmtabletten
Germany:Eplerenon AL 25 mg Filmtabletten
Eplerenon AL 50 mg Filmtabletten
Romania:EPLOHART 25 mg comprimate filmate
EPLOHART 50 mg comprimate filmate
Norway:Eplerenon Medical Valley 25 mg Tablett, filmdrasjert
Eplerenon Medical Valley 50 mg Tablett, filmdrasjert
Sweden:Eplerenon Medical Valley
Eplerenon Medical Valley
Denmark:Eplerenon Medical Valley
Eplerenon Medical Valley
Last review date of this leaflet: December 2021
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.